Relapsing Remitting Multiple Sclerosis Companies

Latest Relapsing-Remitting Multiple Sclerosis Companies Update

• 
  Sep 2023: Concerning the acne treatment ointment Winlevi, Glenmark Pharmaceuticals Ltd. stated that distribution and licensing agreements had been signed with Cosmo Pharmaceuticals NV for South Africa and Europe. Glenmark Specialty SA, the company's branch, and Cosmo Pharmaceuticals NV inked the agreements, according to a statement from Glenmark Pharmaceuticals. According to the business, Winlevi has received FDA approval as a new medication for the topical treatment of acne in individuals 12 years of age and above. Glenmark will handle the product's registration in South Africa and the UK, while Cassiopea will handle the centralized authorization for marketing at the European Medicines Agency (EMA).

• 
  Nov 2023: Months after the US health agency approved the drug, Sage Therapeutics said that the oral postpartum depression (PPD) pill it created with partner Biogen is priced at $15,900 for a complete 14-day course of treatment. The Food and Drug Administration only approved Zurzuvae for postpartum depression in August, despite the companies' request for clearance to treat clinical depression, a far larger market. The first oral medication for the illness that affects one in seven moms after giving birth is called Zurzuvae. Zulresso, another injectable PDD therapy manufactured by Sage, is $34,000 annually. The $15,900 wholesale acquisition price for therapy with Zurzuvae was reportedly below the forecasts of at least two analysts.

• Biogen (US)


• Eisai Co., Ltd (Japan)


• Glenmark Pharmaceuticals (India)


• Merck KGaA (US)


• Novartis AG (Switzerland)


• Sanofi Genzyme (US)


• Teva Pharmaceutical Industries Ltd (Israel)